Differential enhancement of the anti-cancer effect of doxorubicin by Akt inhibitors on human breast cancer cells with differing genetic backgrounds

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 437-442

  Wang, Yan A ^a   Johnson, Stuart K ^a   Brown, Barry L ^a   Dobson, Pauline R M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Akt; Breast cancer; Doxorubicin

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MUTANT; PRIORITY JOURNAL; PROTEIN FUNCTION; STRAIN DIFFERENCE; WILD TYPE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 62849101247     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000242     Document Type: Article

References (16)

1. Wang YA, Johnson SK, Brown BL, McGarragher LM, Al-Sakkaf K, Royds JA and Dobson PRM: Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase (PI3K) inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor (ER) status. Int J Cancer (In press).
2. Bellacosa A, De Feo D, Godwin AK, et al: Molecular alterations of Akt2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
3. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification Akt2 in human pancreatic cells and inhibition of Akt2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636-3641, 1996.
4. Altomare DA, Tanno S, De Rienzo A, et al: Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 88: 470-476, 2003.
5. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999.
6. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407-416, 2002.
7. Edwards J, Krishna NS, Witton CJ and Bartlett JM: Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281, 2003.
8. Gagnon V, Mathieu I, Sexton E, Leblanc K and Asselin E: AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94: 785-795, 2004.
9. Chou TC and Talalay P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454, 1983.
10. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL and Lykkesfeldt AE: Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Rel Cancer 12: 599-614, 2005.
11. De Feo-Jones D, Barnett SF, Fu S, et al: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4: 271-279, 2005.
12. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
13. Barnett SF, De Feo-Jones D, Fu S, et al: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408, 2005.
14. Feun LG, Savaraj N, Bodey GP, et al: Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 44: 3609-3612, 1984.
15. Feun LG, Blessing JA, Barrett RJ and Hanjani P: A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A gynecology oncology group study. Am J Clin Oncol 16: 506-508, 1993.
16. Yang L, Dan HC, Sun M, et al: Akt/protein kinase B signalling inhibitor-2, a selective small molecule inhibitor of Akt signalling with antitumour activity in cancer cells overexpressing Akt. Cancer Res 64: 4394-4399, 2004.